2024 has been an exciting year in which we have seen the exceptional outcomes of all the work and efforts of previous years.
The number of new trials opened has increased by 41%. Studies cover, but are not limited to, areas such as breast, gastrointestinal, genitourinary, gynaecological, lung and sarcoma. This unprecedented increase has meant an increment of 12% in the number of patients treated.
While we are already working to make 2025 another success, below, we highlight some key achievements in 2024.
